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Abstract
Background: Cardiovascular disease (CVD) is a common comorbidity in chronic obstructive pulmonary disease (COPD).
Cardiac troponin (cTn) elevation, indicating myocardial injury, is frequent during acute COPD exacerbations
and associated with increased mortality. The prognostic value of circulating cTnT among COPD patients in
the stable state of the disease is still unknown.
The purpose of the present study was to assess the association between circulating cTnT measured by a high
sensitive assay (hs-cTnT) and all-cause mortality among patients with stable COPD without overt CVD.
Methods: In a prospective cohort study we included 275 patients from the Akershus University Hospital’s outpatient
clinic and from Glittre, a pulmonary rehabilitation clinic. COPD-severity and cardiovascular risk factors were assessed,
and time to all-cause death was recorded during a mean follow-up time of 2.8 years.
Results: One hundred-eighty patients (65%) had hs-cTnT concentrations ≥ the level of detection (5.0 ng/L) and
66 patients (24%) had hs-cTnT above the normal range (≥14.0 ng/L). In total, 47 patients (17%) died. hs-cTnT
concentrations in the ranges <5.0, 5.0–13.9 and ≥14 ng/L were associated with crude mortality rates of 2.8, 4.4
and 11.0 per 100 patient-years, respectively. In adjusted analyses the hazard ratios (95% confidence intervals) for death
were 1.7 (0.8–3.9) and 2.9 (1.2–7.2) among patients with hs-cTnT concentrations 5.0–13.9 and ≥14 ng/L, respectively,
compared to patients with hs-cTnT <5.0 ng/L.
Conclusions: hs-cTnT elevation is frequently present in patients with stable COPD without overt CVD, and
associated with increased mortality, independently of COPD-severity and other cardiovascular risk factors.
Keywords: Chronic obstructive pulmonary disease, Cardiac troponin T, Mortality, Biomarker
Background
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive disease with increasing prevalence [1]. COPD is as-
sociated with severe comorbidities that influence prognosis,
including cardiovascular disease (CVD) [2]. While smoking
is a shared risk factor for both COPD and CVD, COPD has
also been described as an independent risk factor for the
development of CVD [3, 4] and it has repeatedly been
shown that CVD is more common among COPD patients
than in the general population [5–7]. Systemic inflamma-
tion, oxidative stress and hypoxemia may contribute to the
development of CVD in this patient group [8].
Measurement of cardiac specific troponins (cardiac
troponin T and troponin I (cTnT, cTnI)) is incorporated
in the definition and diagnosis of acute myocardial
infarction (MI) [9]. Other acute cardiac and non-cardiac
conditions not directly related to MI have also been as-
sociated with higher troponin levels, such as acute heart
failure, peri-/myocarditis, pulmonary embolism, renal
failure, sepsis, and even strenuous exercise [10, 11]. In
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addition, chronic, low-grade elevations of cardiac troponins
have been observed in patients with stable coronary artery
disease and chronic heart failure [12, 13]. Previously, COPD
has been associated with elevated cTnT in the exacerbated,
as well as in the stable state of the disease [14–17]. More-
over, with highly sensitive methods available, it has been
shown that even levels of cTnT in the low-concentration
range are associated with increased mortality among
patients with acute exacerbations of COPD (AECOPD)
[14, 15, 18]. However, to the best of our knowledge, the
association between cTnT measured during the stable
state of the disease and mortality has not been studied
previously. Accordingly, the objective of the present
study was to relate cTnT measured in patients with




This was a prospective cohort study including 275 patients
with stable COPD from the outpatient clinic at the
Akershus University Hospital and from Glittre Hospital, a
pulmonary rehabilitation hospital in Akershus, Norway.
Patients were included from June 2009 through July 2013
and January 2010 through June 2011, respectively. A stable
state was defined as not having an AECOPD or being
recovered from an AECOPD at least 3 weeks prior to inclu-
sion. Patients with previously established CVD (defined as
history of MI, angina pectoris, percutaneous coronary inter-
vention or stroke) were excluded (n = 16) in the present
analyses. Further details of the recruitment procedure have
been reported previously [16, 19, 20].
Data collection at baseline
History of smoking, hypertension, diabetes and use of
antiplatelet therapy as well as function status by the
modified Medical Research Council (mMRC) dyspnoea
scale were obtained by interview. Systolic blood pres-
sure, weight and height were measured, and BMI calcu-
lated. The presence of left ventricular hypertrophy (LVH,
Sokolow-Lyon criteria), pathological Q- and T-waves
and resting heart rate were evaluated by two physicians
(AN, GE), blinded by troponin levels and outcome. The
arterial partial pressures of oxygen and carbon dioxide
(PaO2 and PaCO2) were obtained from radial arterial
punctures and post-bronchodilatory spirometry measures,
i.e. forced expiratory volume in 1 second (FEV1) and
forced vital capacity (FVC) were registered from the best
of 3 measures. Six-minute walking distance (6MWD) was
performed. Haemoglobin and leucocytes count were ana-
lysed from antecubital venous punctures, while serum and
plasma samples were stored at −80 °C pending analysis of
creatinine and hs-cTnT (cobas e 411 immunoanalyzer,
Roche diagnostics). According to the manufacturer of the
hs-cTnT assay, the lower limit of detection is 5.0 ng/L,
and the 99th percentile in a sample of 533 healthy volun-
teers was 14 ng/L. The lowest hs-cTnT level with 10%
coefficient of variation was 13 ng/L.
Study endpoint
Mortality data was gathered from the National Popula-
tion Registry, which is based on a unique personal iden-
tification number for all Norwegians. The censoring data
(end of follow-up) was set to November 17, 2014.
Ethical considerations
The study was approved by the Data Protection Authority,
and reviewed by the Regional Committee for Research
Ethics. All patients gave their written consent prior to
participation.
Statistical analyses
hs-cTnT levels were categorized in three groups: <5.0 ng/
L, 5.0-13.9 ng/L and ≥14 ng/L. Additionally, the data was
analyzed using hs-cTnT as a continuous variable, logarith-
mically transformed due to skewed distribution. Assuming
a mortality rate at 24 months of follow-up of 0.25 in
patients with troponin T level values > 0.013 ng/L
(assumed n = 100) and 0.13 in patients with troponin level
values <0.013 ng/mL (assumed n = 100), the study will
have >80% power to detect a significant difference (alpha
= 0.05).
The analyses were performed in four steps. First,
univariate associations between hs-cTnT and covariates
at baseline were assessed using Chi-square test, one-way
analysis of variance or Kruskal-Wallis test for categorical
and continuous variables, respectively. Second, age-
adjusted log-rank test for mortality was performed for
covariates if the association between the covariate and
hs-cTnT in the univariate analysis had a p-value < 0.2.
Third, if the age-adjusted log-rank test for mortality for
each covariate revealed a p-value <0.2, we calculated the
crude and adjusted mortality rate ratios (MRR) between
each level of hs-cTnT for each corresponding covariate.
The Mantel-Haenszel test was used to evaluate the statis-
tical significance by the MRR. Moreover, we tested if the
Mantel-Haenszel test revealed a p-value <0.05 for homo-
geneity. Fourth, if the p-value of the Mantel-Haenszel test
was <0.2, the covariate was included in a multivariate pro-
portional hazard Cox regression model subsequently re-
duced by backward elimination. Covariates were removed
from the model if the association between a covariate and
mortality were non-significant and removal of the covari-
ate changed the estimate of coefficient between hs-cTnT
and mortality < 20%.
In the first step, the univariate associations between
hs-cTnT and these covariates were assessed: Gender,
age, FEV1/FVC-ratio, FEV1, BMI, LVH, pathological Q
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and T-wave on the electrocardiogram, history of hyper-
tension, history of diabetes, use of antiplatelet therapy,
smoking status, number of tobacco pack years, heart
rate, systolic BP, haemoglobin, leucocytes, PaO2, PaCO2
and 6MWD. Glomerular filtration rate (GFR) was esti-
mated by the Cockcroft-Gault equation [21]. Before the
subsequent steps, continuous covariates were categorized.
The limits were guided by clinical practice and distribu-
tion in the sample: Age was categorized in three groups:
<62 years, 62–66 years and ≥67 years. Spirometry mea-
sures were categorized by GOLD class, heart rate in <71/
min and ≥71/min (median value), systolic blood pressure
in <120 and ≥120 mmHg (median value), leucocyte count
in <7×10 and ≥7×109/L (median value), GFR in <45, <60
and ≥60 mL/min, partial pressure of oxygen (PaO2) in <8
kPa and ≥8 kPa and 6 minute walking distance was cate-
gorized in <450 and ≥450 m (median value), respectively.
The analyses were performed using STATA 13.1 (Stata
Corp LP, Texas, USA) and SPSS (Version 20; IBM Corp,
New York, NY, USA).
Results
The median hs-cTnT was 6.3 ng/L (interquartile range
5–13 ng/L). The prevalences of patients having hs-cTnT
<5.0 ng/L, 5.0–13.9 ng/L and ≥14 ng/L were 35%, 41%
and 24%, respectively. Mean age (SD) at inclusion was
64 (7.2) years and 146 (53%) were female. Univariate
associations between hs-cTnT categories and covariates
using the inclusion criterion of a p-value <0.2 were
observed for the following covariates (Table 1): Age,
gender, GOLD class, history of hypertension and dia-
betes, current smoking, systolic blood pressure, heart
rate, pathological Q-wave, PaO2, leucocyte count, GFR,
6MWD and mMRC-score.
The median time to death or censoring time was
2.8 years. 47 patients (17.1%) died during the follow-
up period. The crude mortality rates per 100 patient-
years (95% confidence interval) were 2.8 (1.4–5.3), 4.4
(2.7–7.0) and 11.0 (7.2–16.9) in patients with hs-
cTnT <5.0 ng/L, 5.0–13.9 ng/L and ≥14 ng/L,
respectively.
Age-adjusted associations between covariates and
mortality were observed for history of diabetes, GOLD-
class, pathological Q-wave, leucocyte count, creatinine,
heart rate, 6MWD and mMRC >2 (Table 2). The number
of deaths and mortality rates across hs-cTnT levels,
stratified by the covariates significantly associated with
hs-cTnT, are shown in Table 3.
Table 1 Distribution of TnT by relevant covariates at baseline
Covariate High sensitivity Troponin T, ng/L p-value*
<5.0 (n = 95) 5.0–13.9 (n = 114) ≥14.0 (n = 66)
Age, years, mean (SD) 62 (7.3) 64 (6.7) 67 (7.2) <0.001
Female, n (%) 64 (67) 56 (49) 26 (39) <0.001
BMI, mean (SD) 24.7 (5.1) 24.7 (5.4) 24.5 (5.4) 0.962
GOLD class III/IV, n (%) 46 (48) 60 (53) 51 (77) 0.001
Hypertension, n (%) 32 (34) 36 (32) 36 (55) 0.006
Diabetes, n (%) 4 (4) 1 (1) 9 (14) 0.001
Current smoking, n (%) 34 (36) 29 (26) 11 (17) 0.025
Pack years, mean (SD) 35 (16.1) 35 (16.9) 37 (19.5) 0.686
Systolic BP, mmHg mean (SD) 132 (21.9) 138 (20.1) 138 (19.5) 0.080
Hemoglobin, g/dL mean (SD) 14.1 (1.2) 14.3 (1.1) 15.7 (13.7) 0.285
Heart rate per min, mean (SD) 70 (13.3) 71 (12.9) 75 (13.9) 0.067
LVH, n (%) 1 (1) 5 (5) 2 (3) 0.358
Pathologic Q-wave, n (%) 5 (5) 6 (5) 9 (14) 0.067
Use of antiplatelet therapy, n (%) 10 (10) 12 (11) 5 (8) 0.781
PaO2, kPa, mean (SD) 9.0 (1.1) 9.3 (1.3) 8.9 (1.3) 0.058
PaCO2, kPa, mean (SD) 5.4 (0.7) 5.4 (0.8) 5.5 (0.8) 0.847
Leucocytes, x109/L, mean (SD) 7.0 (1.7) 7.1 (1.9) 7.8 (2.3) 0.028
GFR, mL/min, mean (SD) 89 (3) 89 (3) 79 (4) 0.044
6MWD, meters, mean (SD) 465 (109) 455 (123) 365 (104) <0.001
mMRC >2, n (%) 42 (44) 58 (51) 47 (71) 0.003
AECOPD during last year, n (%) 33 (35) 40 (36) 28 (43) 0.571
*Analysis of variance, Pearson Chi-Square, Fisher’s exact test, as appropriate
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Overall, the crude MRR across categories of hs-cTnT
was 2.1 (95% CI: 1.4–3.1). The bivariate analyses show
that the crude and adjusted MRR were similar, thus,
there was no meaningful confounding in the data
regarding mortality. The Mantel-Haenszel test did not
reveal a p-value <0.05 for homogeneity for any of the co-
variates which is why we assume that there was no effect
modification of relevant variables.
Age, gender, GOLD class, 6MWD, history of diabetes,
leucocyte count and pathological Q-wave were included
in the final Cox regression model (Table 4).
There was a positive association between hs-cTnT and
mortality (p for trend < 0.001). In adjusted analyses,
using patients with hs-cTnT <5.0 ng/l as the reference,
the hazard ratios (95% confidence intervals) for death
were 1.7 (0.8–3.9) and 2.9 (1.2–7.2) among patients with
hs-cTnT concentrations 5.0–13.9 and ≥14 ng/L, respect-
ively. We also investigated the association between mor-
tality and hs-cTnT expressed as a continuous variable.
One unit increase in the natural logarithm of hs-cTnT
in the final Cox model was associated with a hazard ra-
tio (95% CI) of 1.7 (1.2–2.4). We observed no significant
changes in the results after exclusion of two patients
with hs-cTnT values >100 ng/L. The global test of the
model did not violate the proportional hazards assump-
tion, neither did the single covariates with the exception
of gender. However, gender did not influence the associ-
ation between troponin and mortality.
Discussion
The main finding in this study is that cTnT-elevation
above the 99th percentile in patients with stable COPD
without overt CVD is associated with increased mortality,
independently of COPD-severity and traditional cardio-
vascular risk factors.
While the diagnostic properties of elevated troponins
are important in patients presenting with chest pain, the
properties as a prognostic marker have received consid-
erable interest in acute coronary syndrome, as well as in
other conditions such as stable coronary heart disease,
heart failure, pulmonary embolism, renal failure, ische-
mic stroke and sepsis [12, 22–27]. To the best of our
knowledge this is the first prospective study to assess the
Table 2 Mortality rates (MR) by relevant categorical covariates
Covariate m (MR) RR p-value*
unadjusted Age-adjusted
Age, years 1.81 0.002 -
< 62 8 (2.6)
62–66 12 (4.2)
≥ 67 27 (8.7)
Gender 1.30 0.416 0.379
Male 19 (4.5)
Female 28 (5.8)
Current smoking 0.93 0.864 0.768
Yes 11 (4.9)
No 36 (5.3)
Hypertension 1.14 0.658 0.936
Yes 19 (5.6)
No 28 (5.0)
Diabetes 2.94 0.007 0.011
Yes 6 (14.1)
No 41 (4.8)
GOLD class 2.95 0.002 0.004
I–II 10 (2.5)
III–IV 37 (7.4)
PaO2 < 8 kPa 1.65 0.134 0.336
Yes 12 (7.7)
No 35 (4.7)
Pathologic Q-wave 2.39 0.028 0.071
Yes 7 (11.6)
No 40 (4.9)
Antiplatelet therapy 0.81 0.690 0.791
Yes 4 (4.3)
No 43 (5.3)
Leucocytes≥ 7 × 109/L 2.52 0.004 0.003
Yes 34 (7.4)
No 13 (2.9)
Heart rate >71 per min 2.48 0.004 0.004
Yes 34 (7.3)
No 13 (2.9)
Systolic blood pressure >140 mmHg 1.33 0.583 0.999
No 6 (4.1)
Yes 41 (5.4)
GFR 0.40 0.008 0.025
< 45 mL/min 4 (24.5)
45–60 mL/min 8 (6.4)
> 60 mL/min 35 (4.6)
Table 2 Mortality rates (MR) by relevant categorical covariates
(Continued)
6MWD < 450 m 3.63 <0.001 0.002
Yes 35 (8.7)
No 12 (2.4)
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association between cTnT and long-term mortality in
patients with stable COPD. The present finding is in line
with studies in other patient populations in which small
increments of circulating concentrations of cTnT are
associated with poor outcome above and beyond traditional
risk factors [12, 28, 29]. The fact that hs-cTnT in our popu-
lation was associated with total mortality independently of
strong predictors of mortality such as the components of
Table 3 Mortality, mortality rates, mortality rate ratio expressed as score test for trend for a one unit increase in troponin category,
by selected covariates
High-sensitivity troponin, ng/L MRR (95% CI)
<5.0 5.0–13.99 ≥14
(n = 95) (n = 114) (n = 66)
Covariate m (MR) m (MR) m (MR) Unadjusted Adjusteda
All, crude 9 (2.8) 17 (4.4) 21 (11.0) 2.1 (1.4–3.1) -
Age at inclusion, years
< 62 2 (1.4) 3 (2.4) 3 (7.0) 2.4 (0.9–6.6) 1.9 (1.3–2.8)
62–66 3 (3.1) 4 (3.2) 5 (7.8) 1.7 (0.8–3.6)
≥ 67 4 (4.6) 10 (7.2) 13 (15.5) 1.9 (1.1–3.1)
Gender
Female 8 (3.7) 9 (4.7) 11 (15.3) 2.2 (1.3–3.8) 2.3 (1.5–3.4)
Male 1 (0.9) 8 (4.1) 10 (8.4) 2.3 (1.2–4.3)
Diabetes
Yes 0 (0) 0 (0) 6 (25.7) 2.5 (1.1–5.9) 1.9 (1.3–2.8)
No 9 (2.9) 17 (4.5) 15 (8.9) 1.8 (1.2–2.7)
GOLD class
I–II 2 (1.1) 4 (2.2) 4 (9.5) 3.4 (1.3–8.7) 1.8 (1.2–2.6)
III–IV 7 (4.6) 13 (6.4) 17 (11.4) 1.6 (1.1–2.4)
PaO2 < 8 kPa
Yes 3 (5.3) 2 (3.2) 7 (19.6) 2.3 (1.1–4.8) 2.1 (1.4–3.0)
No 6 (2.2) 15 (4.6) 14 (9.0) 2.1 (1.4–3.1)
Pathologic Q-wave
Yes 1 (7.4) 1 (5.2) 5 (17.9) 1.7 (0.7–4.4) 2.0 (1.4–2.9)
No 8 (2.6) 16 (4.4) 16 (10.3) 2.1 (1.4–3.2)
Leucocytes > 7×109/L
Yes 6 (3.6) 12 (6.7) 16 (14.2) 2.0 (1.3–3.1) 2.0 (1.4–2.9)
No 3 (1.9) 5 (2.4) 5 (6.4) 1.9 (0.9–4.2)
Heart rate, > 71 per min
Yes 7 (4.8) 11 (5.9) 16 (12.2) 1.7 (1.1–2.6) 1.9 (1.3–2.8)
No 2 (1.1) 6 (3.0) 5 (8.3) 2.9 (1.3–6.4)
GFR
< 45 mL/min 0 (0) 1 (12.1) 3 (37.2) 2.8 (0.4–19.8) 1.9 (1.2–3.0)
45–60 mL/min 1 (1.7) 3 (9.3) 4 (11.4) 2.2 (1.0–5.0)
> 60 mL/min 8 (3.0) 9 (3.7) 14 (9.5) 1.9 (1.2–2.9)
6MWD, <450 m
Yes 7 (5.6) 12 (7.8) 16 (12.6) 1.5 (1.0–2.3) 1.7 (1.2–2.5)
No 2 (1.0) 5 (2.1) 5 (7.8) 3.1 (1.4–7.3)
mMRC > 2
Yes 6 (4.4) 10 (5.0) 17 (12.6) 1.8 (1.2–2.8) 1.9 (1.3–2.8)
No 3 (1.6) 7 (3.7) 4 (7.1) 2.2 (1.0–4.8)
aMantel Haenzel test
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the BODE index, makes hs-cTnT a possible candidate for
early risk prediction in stable COPD patients.
Given that COPD is primarily a pulmonary disease, it
is of interest to consider the possible pathophysiological
mechanisms underlying cTnT elevation in COPD. cTnT
is exclusively synthesized in cardiomyocytes, and the
presence of cTnT in serum implicates leakage of cTnT
into the circulation by cell damage or increased cell
turnover. The most common causes for chronic, low-
grade cTnT-increase are ischemic heart disease and con-
ditions characterized by increased cardiac strain [30].
The participants in the present study were without overt
CVD, but we cannot exclude the possibility that patients
with increases in cTnT had undiagnosed coronary artery
disease. Indeed 20 (7%) of the patients had a patho-
logical Q-wave on the ECG, but interestingly this was
not significantly related to hs-cTnT concentrations. N-
terminal prohormone of B-type natriuretic peptide (NT-
proBNP), an indicator of heart failure, was not measured
in all participants, but a previous analysis in a subgroup
(n = 101) showed normal NT-proBNP levels and no as-
sociation with cTnT [16].
Pertinent to the hypothesis that COPD might be a risk
factor for CVD, factors known to be associated with sec-
ondary cardiovascular effects, such as systemic hypoxemia
and systemic inflammation, were evaluated. In the present
study only 45 (16%) of the patients had arterial hypoxemia,
and we found no statistically significant association between
partial pressure of oxygen and troponin or mortality.
Leucocyte count as an indicator of elevated baseline
inflammation was associated with increased levels of tropo-
nin and risk of death in the present study. Such associations
have been reported earlier [16, 31]. Inflammatory activity
might promote the development and worsening of subclin-
ical atherosclerotic disease and thereby prognosis in this
population. There is also a possibility that cTnT elevation is
mediated by an inflammatory effect on the cardiomyocytes.
In that case, leukocyte count represents a mediator and
should not been included as a covariate [32]. A higher
inflammatory state has also been linked to worse prognosis
and more frequent exacerbations in COPD [33].
Another possible mechanism underlying cTnT eleva-
tion in stable COPD might be increased right ventricular
strain associated with pulmonary hypertension [34]. Hattori
et al. have described an association between hs-cTnT with
right heart pressure in stable COPD [31]. It is conceivable
that the involvement of the right heart accounts for both
elevated hs-cTnT and increased mortality in stable COPD
independently of lung function.
The current study extends previous data concerning
the prognostic value of hs-cTnT in patients with
acute exacerbation of COPD. However, although ele-
vated cTn concentrations are associated with poor
outcome, it is not established how clinicians should
approach this situation neither in COPD nor in other
patient groups.
Study limitations
In order to further evaluate the discriminative power of
cTnT in risk stratification, larger study samples are needed.
Serial hs-cTnT measurement would provide us with a
better possibility to evaluate the associations between cTnT
and mortality in relation to COPD-progression and other
cardiovascular risk factors. The study would have benefitted
from baseline cardiac imaging, both with regard to undiag-
nosed coronary heart disease and myocardial function. A
stable state was defined as <3 weeks since last exacerbation.
This is a shorter period than in several other COPD-
studies. However, excluding patients having an exacerbation
during the last 3 months prior to inclusion did not change
the main results (data not shown). We lack information
regarding the cause of death, which could have given us
additional insight in the relation between cTnT and cardio-
vascular deaths.
Conclusion
cTnT, measured by a high sensitivity assay, was associ-
ated with increased all-cause mortality, independently of
COPD-severity.
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Table 4 Multivariate adjusted hazard ratios for all-cause death




≥ 14 2.9 1.2–7.2




≥ 67 2.7 1.2–6.0
p for trend 0.002
Female versus maleb 1.9 0.99–3.8
Gold class III/IV versus I/II 1.8 0.84–3.8
Pathologic Q-wave, yes versus no 1.5 0.62–3.6
Diabetes, yes versus no 1.9 0.8–5.1
Leucocyte count > 7×109/L, yes versus no 2.3 1.2–4.6
6MWD < 450 m, yes versus no 1.6 0.7–3.3
aCox regression analysis
bviolated the proportional hazard assumption, i.e. the HR changed during
the follow-up
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